NASDAQ:INDV Indivior (INDV) Stock Price, News & Analysis $15.10 -0.16 (-1.05%) (As of 07/5/2024 ET) Add Compare Share Share Today's Range$14.92▼$15.1950-Day Range$15.10▼$18.4852-Week Range$14.38▼$24.90Volume79,158 shsAverage Volume90,634 shsMarket Capitalization$2.08 billionP/E Ratio1,510.00Dividend YieldN/APrice Target$36.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Get Indivior alerts: Email Address Indivior MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside138.4% Upside$36.00 Price TargetShort InterestHealthy0.07% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.14Based on 11 Articles This WeekInsider TradingN/AProj. Earnings Growth29.02%From $1.93 to $2.49 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.73 out of 5 starsMedical Sector213th out of 879 stocksPharmaceutical Preparations Industry93rd out of 417 stocks 3.5 Analyst's Opinion Consensus RatingIndivior has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageIndivior has received no research coverage in the past 90 days.Read more about Indivior's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.07% of the float of Indivior has been sold short.Short Interest Ratio / Days to CoverIndivior has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Indivior has recently decreased by 18.96%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldIndivior does not currently pay a dividend.Dividend GrowthIndivior does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for INDV. Previous Next 2.9 News and Social Media Coverage News SentimentIndivior has a news sentiment score of 0.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Indivior this week, compared to 2 articles on an average week.Search Interest1 people have searched for INDV on MarketBeat in the last 30 days. MarketBeat Follows4 people have added Indivior to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Indivior insiders have not sold or bought any company stock.Percentage Held by Institutions60.33% of the stock of Indivior is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Indivior's insider trading history. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Indivior are expected to grow by 29.02% in the coming year, from $1.93 to $2.49 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Indivior is 1,510.00, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 120.46.Price to Earnings Ratio vs. SectorThe P/E ratio of Indivior is 1,510.00, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 100.71.Price to Book Value per Share RatioIndivior has a P/B Ratio of 40.81. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Indivior's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the Markets270x more lucrative than NVIDIA???If you've missed out on NVIDIA's recent 1,600% run... Don't worry. Because there's one AI stock that could be a lot more lucrative.Get the ticker here >>> About Indivior Stock (NASDAQ:INDV)Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.Read More INDV Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart INDV Stock News HeadlinesJuly 3, 2024 | americanbankingnews.comEquities Analysts Offer Predictions for Indivior PLC's FY2024 Earnings (NASDAQ:INDV)July 3, 2024 | americanbankingnews.comNorthland Capmk Weighs in on Indivior PLC's Q2 2024 Earnings (NASDAQ:INDV)July 7, 2024 | Paradigm Press (Ad)Man who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.June 27, 2024 | americanbankingnews.comIndivior (NASDAQ:INDV) Shares Down 3% June 18, 2024 | prnewswire.comIndivior Announces the Publication of New Data on the Comparative Effectiveness of Intranasal (IN) Nalmefene (OPVEE 2.7mg) and IN Naloxone (4 mg) in a Translational Model Assessing the Impact of a Synthetic Opioid Overdose on Respiratory Depression and Cardiac ArrestJune 10, 2024 | prnewswire.comIndivior Announces Dosing of First Subject with INDV-2000 in a Phase 2 Study Assessing the Safety and Efficacy of INDV-2000 in Individuals with Opioid Use DisorderJune 5, 2024 | globenewswire.comOpioid Use Disorder in the 7MM: Epidemiology Insights and Forecast 2024-2034 Featuring Detailed Analysis of Marketed and Late-Stage Pipeline Drugs, Including Subutex and INDV-2000 (Indivior)May 24, 2024 | finance.yahoo.comWith 59% ownership, Indivior PLC (LON:INDV) boasts of strong institutional backingJuly 7, 2024 | Paradigm Press (Ad)Man who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.May 23, 2024 | prnewswire.comIndivior to Host Analyst Teach-in Event in New York City; Reconfirms Full Year 2024 GuidanceApril 26, 2024 | finance.yahoo.comIndivior PLC (INDV) Q1 2024 Earnings Call Transcript Highlights: Navigating Challenges with ...April 25, 2024 | msn.comINDV Stock Earnings: Indivior Misses EPS, Misses Revenue for Q1 2024April 25, 2024 | prnewswire.comIndivior Announces Q1 2024 Financial ResultsApril 4, 2024 | msn.comAddex spinoff Neurosterix debuts with $63m for developing neurological therapiesApril 4, 2024 | wsj.comIndivior PLCMarch 11, 2024 | prnewswire.comIndivior Announces Publication Demonstrating that OPVEE® (nalmefene) Nasal Spray Rapidly Reverses Effects of Opioid-Induced Respiratory Depression in Head-to-Head Study Against Intranasal NaloxoneMarch 8, 2024 | bizjournals.comFDA inspection flags public company's Raleigh facilityFebruary 29, 2024 | prnewswire.comCourt Provides Final Approval of Settlement with Direct Purchaser Class in the Multidistrict Antitrust Litigation; Final Court Approval Concludes the Antitrust Multidistrict LitigationSee More Headlines Receive INDV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Indivior and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/25/2024Today7/07/2024Next Earnings (Estimated)7/25/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:INDV CUSIPN/A CIK1625297 Webwww.indivior.com Phone804-379-1090Fax804-379-1215Employees1,164Year FoundedN/APrice Target and Rating Average Stock Price Target$36.00 High Stock Price Target$37.00 Low Stock Price Target$35.00 Potential Upside/Downside+138.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)$0.01 Trailing P/E Ratio1,510.00 Forward P/E Ratio7.82 P/E GrowthN/ANet Income$2 million Net Margins0.44% Pretax Margin0.53% Return on Equity842.72% Return on Assets12.42% Debt Debt-to-Equity Ratio23.50 Current Ratio0.92 Quick Ratio0.74 Sales & Book Value Annual Sales$1.09 billion Price / Sales1.90 Cash Flow$1.82 per share Price / Cash Flow8.29 Book Value$0.37 per share Price / Book40.81Miscellaneous Outstanding Shares137,880,000Free FloatN/AMarket Cap$2.08 billion OptionableNot Optionable Beta0.69 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMr. Mark CrossleyCEO & Executive DirectorMr. Ryan PreblickCFO & Executive DirectorDr. Christian HeidbrederChief Scientific OfficerMr. Jason ThompsonVice President of Investor RelationsMs. Cynthia CetaniChief Integrity & Compliance OfficerMr. Jeffrey W. Burris (Age 52)Chief Legal Officer Mr. Jon FogleChief Human Resources OfficerMr. Richard SimkinChief Commercial OfficerMr. Hillel WestChief Manufacturing & Supply OfficerMr. Vishal KaliaSVP of US Treatment Access, Support Programs & Business Insights and Chief Impact & Strategy OfficerMore ExecutivesKey CompetitorsLegend BiotechNASDAQ:LEGNAscendis Pharma A/SNASDAQ:ASNDRoivant SciencesNASDAQ:ROIVCerevel TherapeuticsNASDAQ:CEREIntra-Cellular TherapiesNASDAQ:ITCIView All CompetitorsInstitutional OwnershipJanus Henderson Group PLCBought 54,750 shares on 5/16/2024Ownership: 0.319%FourWorld Capital Management LLCBought 103,394 shares on 5/16/2024Ownership: 0.075%Quadrature Capital LtdBought 71,113 shares on 5/15/2024Ownership: 0.052%Toronto Dominion BankBought 769,000 shares on 5/14/2024Ownership: 1.519%Vanguard Group Inc.Bought 12,526 shares on 5/10/2024Ownership: 4.288%View All Institutional Transactions INDV Stock Analysis - Frequently Asked Questions How have INDV shares performed this year? Indivior's stock was trading at $15.27 at the beginning of 2024. Since then, INDV shares have decreased by 1.1% and is now trading at $15.10. View the best growth stocks for 2024 here. How were Indivior's earnings last quarter? Indivior PLC (NASDAQ:INDV) issued its earnings results on Thursday, April, 25th. The company reported $0.37 EPS for the quarter, missing the consensus estimate of $0.38 by $0.01. The business had revenue of $284 million for the quarter, compared to the consensus estimate of $300 million. Indivior had a trailing twelve-month return on equity of 842.72% and a net margin of 0.44%. How do I buy shares of Indivior? Shares of INDV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:INDV) was last updated on 7/7/2024 by MarketBeat.com Staff From Our PartnersBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredObama’s DNC coupAs we approach the Democratic National Convention in August... many sense a Biden swap-out is looming. In f...Stansberry Research | Sponsored270x more lucrative than NVIDIA???If you've missed out on NVIDIA's recent 1,600% run... Don't worry. Because there's one AI stock that cou...Behind the Markets | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredExposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredGrab Your Free Bitcoin Today!And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a v...Crypto Swap Profits | SponsoredThe asset beating inflation by 4xCentral Bank Gold Heist In Progress Central banks are buying gold at record rates... and billionaire invest...Colonial Metals | SponsoredObama wins Presidential debate When I said Obama would seek a third term… They called me a conspiracy theorist, they said it couldn’t happ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Indivior PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Indivior With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
